Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ian McDonald
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Beta
- 0.09
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 69.70
Financials
Net Income
$-2.46MEBITDA
$-11.71MFree Cash Flow
$-8.42MEPS (diluted)
$-0.26Shares Outstanding (diluted)
9.83M+749.2%Operating Expenses
$11.71MCash & Debt
$308.33MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.23M | $-1.78 |
| 2024 | $0.00 | $-2.80M | $-0.65 |
| 2023 | $0.00 | $-7.37M | $-1.98 |
| 2022 | $0.00 | $-14.96M | $-6.15 |
| 2021 | $0.00 | $-8.65M | $-4.74 |
| 2020 | $0.00 | $-480.4K | $-0.38 |
| 2019 | $0.00 | $-236.2K | $-0.06 |
Valuation
DRUGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
55-8.33%Social Signal Score
Mentions (10)
- Newsbusinesswire.com·6h ago·Negative
DRUG Investors Have Opportunity to Join Bright Minds Biosciences Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $DRUG--DRUG Investors Have Opportunity to Join Bright Minds Biosciences Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsyoutube.com·5d ago·Negative
DRUG CRACKDOWN: US deploys drones to combat traffickers at border Rep. Pat Fallon, R-Texas, discusses the deployment of drones at the southern border as drug traffickers ramp up their own drone operations on ‘The Evening Edit.' #foxbusiness #fox #media #breakingnews #us #usa #new #news #breaking #theeveningedit #patfallon #fallon #drones #dronetechnology #bordersecurity #southernborder #drugtrafficking #drugcartels #drugsmuggling #borderpatrol #homelandsecurity #texas #mexico #national security …
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
Bright Minds Biosciences: Promising Catalysts Despite The FDA Setback Bright Minds Biosciences' early epilepsy results support further R&D, although small uncontrolled trials still leave some uncertainties about efficacy and safety. DRUG's further studies or protocol changes could become a path past the FDA's recent hold decision. Naturally, that could involve more R&D costs, but in the long run I think DRUG still has a path forward for BMB-101.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…date About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that the U.S. Food and Drug Administration (“FDA”) has notified the Company via email that its investigational new drug application (“IND”) for Developmental and Epileptic Encephalopathies (“DEEs”) and related Protocol BMB-101-105 has been placed on a partial clinical …
View source ↗ - Newsprnewswire.com·27d ago·Negative
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…ciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Founda…
View source ↗ - Newsglobenewswire.com·79d ago·Negative
…nces to Present at Upcoming Conferences NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: Cantor Global Healthcare Co…
View source ↗ - Newszacks.com·87d ago·Neutral
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·88d ago·Negative
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·104d ago·Negative
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗
Earnings
Tue, Dec 22(in 4 weeks)
Consensus estimate $-1.07 per share
Typical surprise +27.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.17 vs $-1.39beat
- Wed, May 20$-0.80 vs $-1.06beat
- Thu, Feb 12$-0.70 vs $-0.98beat
- Tue, Dec 23$-0.41 vs $-0.56beat
- Thu, Aug 14$-0.53 vs $-0.59beat
- Thu, May 15$-0.29 vs $-0.39beat
Estimates and results for DRUG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRUG officers and directors.
- Bought
- $7.2m
- Sold
- $9.8m
12 trades
1 trade
- Cormorant Asset Management, Lpsold
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DRUG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
